IP Library Granted Patent US 8,586,771
Granted Patent B1
US 8,586,771 · App. 13/787,556 · Granted Nov 19, 2013

Processes of preparing estolide compounds that include removing sulfonate residues

Inventors: Marlon Lutz (Grayslake, IL); Igor Likhotvorik (Wilmette, IL); Chris Arnold (Mount Prospect, IL); Travis Thompson (Anaheim, CA); Dean Kent Hoglen (Baton Rouge, LA); Eric Lee Williams (Zachary, LA)
Assignee: Biosynthetic Technologies, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,586,771
App. No.
13/787,556
Granted
Nov 19, 2013
Kind
B1
Abstract

Provided herein are processes of preparing sulfonated estolide compounds, and the removal of sulfonate residues from those compounds to provide desulfonated estolide base oils. Exemplary sulfonated estolide compounds include those selected from the formula: wherein z is an integer selected from 0 to 15; q is an integer selected from 0 to 15; x is, independently for each occurrence, an integer selected from 0 to 20; y is, independently for each occurrence, an integer selected 0 to 20; n is equal to or greater than 0; R 6 is selected from —OH, optionally substituted alkyl, and optionally substituted aryl; and R 2 is selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched, wherein each fatty acid chain residue of said compounds is independently optionally substituted.

Claims (33)

1. A process of producing an estolide base oil comprising

providing at least one first estolide compound having at least one mesylate residue, wherein said at least one first estolide compound is selected from compounds of Formula III:

wherein

z is an integer selected from 0 to 12;

q is an integer selected from 0 to 10;

x is, independently for each occurrence, an integer selected from 0 to 10;

y is, independently for each occurrence, an integer selected from 0 to 10;

n is an integer selected from 0 to 8;

R 6 is methyl; and

R 2 is selected from hydrogen and optionally substituted alkyl that is saturated or unsaturated, and branched or unbranched,

wherein each fatty acid chain residue is unsubstituted; and

eliminating the at least one mesylate residue by exposing the at least one first estolide compound to heat and/or basic conditions to provide a demesylated estolide compound that is unsaturated at the site of elimination.

2. The process according to claim 1 , wherein eliminating said at least one mesylate residue includes contacting the at least one first estolide compound with a base.

3. The process according to claim 2 , wherein the base comprises at least one metal hydroxide.

4. The process according to claim 1 , wherein eliminating said at least one mesylate residue includes heating the at least one first estolide compound to a temperature that is greater than 20° C.

5. The process according to claim 4 , wherein eliminating said at least one mesylate residue includes heating the at least one first estolide compound to a temperature of at least 75° C.

6. The process according to claim 5 , wherein eliminating said at least one mesylate residue includes heating the at least one first estolide compound to a temperature of at least 100° C.

7. The process according to claim 6 , wherein eliminating said at least one mesylate residue includes heating the at least one first estolide compound to a temperature of at least 160° C.

8. The process according to claim 5 , wherein eliminating said at least one mesylate residue includes heating the at least one first estolide compound under reduced pressure that is less than 1 atm abs.

9. The process according to claim 8 , wherein the reduced pressure is 250 torr abs or less.

10. The process according to claim 9 , wherein the reduced pressure is 25 torr abs or less.

11. The process according to claim 1 , further comprising hydrogenating the demesylated estolide compound to provide at least one saturated estolide compound.

12. The process according to claim 1 , wherein x is, independently for each occurrence, an integer selected from 7 and 8.

13. The process according to claim 12 , wherein y is, independently for each occurrence, an integer selected from 7 and 8.

14. The process according to claim 1 , wherein R 2 is an unsubstituted alkyl that is saturated or unsaturated, and branched or unbranched.

15. The process according to claim 14 , wherein R 2 is selected from C 6 to C 12 alkyl.

16. The process according to claim 15 , wherein R 2 is saturated and branched.

17. The process according to claim 1 , wherein z is an integer selected from 7 and 8.

18. The process according to claim 17 , wherein q is an integer selected from 7 and 8.

19. The process according to claim 1 , wherein x+y is, independently for each fatty acid chain residue, an integer selected from 13 to 15.

20. The process according to claim 2 , wherein the base is a carboxylate salt.

21. The process according to claim 2 , wherein the base is selected from one or more of a tertiary amine or an aromatic amine.

22. The process according to claim 1 , further comprising esterifying the at least one first estolide compound with at least one alcohol to provide an esterified estolide compound having at least one mesylate residue.

Assignments (13)
ASSIGNMENT OF SECURITY INTEREST Recorded Mar 23, 2018
From: EVONIK OIL ADDITIVES USA, INC.
To: BIOSYN HOLDINGS, LLC
Reel/Frame 045684/0293 →
ASSIGNMENT OF SECURITY INTEREST Recorded Mar 23, 2018
From: BP TECHNOLOGY VENTURES INC.
To: BIOSYN HOLDINGS, LLC
Reel/Frame 045688/0600 →
ASSIGNMENT OF SECURITY INTEREST Recorded Mar 23, 2018
From: EVONIK CORPORATION
To: BIOSYN HOLDINGS, LLC
Reel/Frame 045860/0547 →
RELEASE OF SECURITY INTEREST Recorded Feb 13, 2018
From: SILICON VALLEY BANK
To: BIOSYNTHETIC TECHNOLOGIES, LLC
Reel/Frame 044916/0936 →
SECURITY INTEREST Recorded Jan 30, 2018
From: BIOSYNTHETIC TECHNOLOGIES, LLC
To: BP TECHNOLOGY VENTURES INC.
Reel/Frame 045196/0587 →
SECURITY INTEREST Recorded Mar 18, 2016
From: BIOSYNTHETIC TECHNOLOGIES, LLC
To: EVONIK OIL ADDITIVES USA, INC.
Reel/Frame 038146/0859 →
SECURITY INTEREST Recorded Nov 30, 2015
From: BIOSYNTHETIC TECHNOLOGIES, LLC
To: EVONIK CORPORATION
Reel/Frame 037162/0364 →
SECURITY INTEREST Recorded Dec 20, 2014
From: BIOSYNTHETIC TECHNOLOGIES, LLC
To: SILICON VALLEY BANK
Reel/Frame 034562/0322 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: LUTZ, MARLON; LIKHOTVORIK, IGOR; ARNOLD, CHRIS
To: REGIS TECHNOLOGIES, INC.
Reel/Frame 030287/0207 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: REGIS TECHNOLOGIES, INC.
To: BIOSYNTHETIC TECHNOLOGIES, LLC
Reel/Frame 030287/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: HOGLEN, DEAN KENT; WILLIAMS, ERIC LEE
To: ALBEMARLE CORPORATION
Reel/Frame 030287/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: ALBEMARLE CORPORATION
To: BIOSYNTHETIC TECHNOLOGIES, LLC
Reel/Frame 030287/0420 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2013
From: THOMPSON, TRAVIS
To: BIOSYNTHETIC TECHNOLOGIES, LLC
Reel/Frame 030289/0152 →
Continuity (1)
Provisional Application 61661010 · Jun 18, 2012